Species Discovery Boom Offers Pharma a Fresh Pipeline as Natural Product Research Rebounds

The pace of biological discovery is accelerating at a time when the pharmaceutical industry desperately needs new sources of chemical diversity. Scientists described a record 17,044 new species of plants, animals, and microorganisms in 2020, the most recent year with complete taxonomic data, according to Species2000 and the Integrated Taxonomic Information System. That figure represents a 57% increase from roughly a decade earlier, driven by DNA barcoding technologies, expanded field surveys in understudied regions, and computational tools that can distinguish morphologically similar organisms.

For drug developers, each newly cataloged species represents a potential source of novel bioactive compounds. Natural products have historically been the foundation of modern medicine: roughly 60% of approved drugs derive from or are inspired by natural chemicals, from aspirin's willow bark origins to the statins found in soil fungi. Yet the sector contracted sharply from the 1990s through the 2010s as high-throughput synthetic chemistry screening became cheaper and genomic approaches promised faster paths to leads. Major pharmaceutical companies including Pfizer, Roche, and Merck shuttered or downsized dedicated natural product research units during that period.

That trend is reversing. A confluence of factors, including the antibiotics resistance crisis, the limitations of purely synthetic compound libraries, and advances in metabolomics and artificial intelligence, has reignited interest in bioprospecting. The global natural products market in drug discovery was valued at approximately $3.2 billion in 2023 and is projected to grow at a compound annual rate of 7.4% through 2030, according to Grand View Research.

The Compounds Hiding in Undocumented Life

The logic is straightforward. Evolution has spent billions of years optimizing chemical defenses, signaling molecules, and metabolic pathways across millions of species. Many of these molecules have potent pharmacological effects in human cells because the underlying biochemistry is conserved across life. Fungi produce antibiotics to outcompete bacteria. Marine sponges synthesize cytotoxic compounds to deter predators. Tropical plants generate alkaloids that interfere with nervous systems.

The problem is that most of this chemical space remains unexplored. Estimates suggest that only about 10% of Earth's roughly 8.7 million eukaryotic species have been formally described, and the fraction that has been chemically characterized is far smaller. Among microorganisms, the gap is even wider: environmental DNA studies indicate that fewer than 1% of bacterial and archaeal species have been cultured in laboratories.

"We are essentially sitting on a massive, uncharacterized library of chemistry," said Marcel Jaspars, a natural products chemist at the University of Aberdeen and co-founder of the biotech startup Bristol Natural Products. "The challenge has always been access and screening throughput, not the existence of interesting molecules."

Several recent discoveries illustrate the potential. In 2024, researchers at the University of California, San Diego identified a class of peptides from a previously undescribed marine cyanobacterium that showed potent activity against methicillin-resistant Staphylococcus aureus (MRSA) in preclinical models. The compounds, dubbed cyanocapsins, work through a mechanism distinct from existing antibiotics, potentially sidestepping established resistance pathways. The findings were published in Nature Chemical Biology.

Separately, a team at the Swiss Federal Institute of Technology (ETH Zurich) used machine learning to predict bioactivity across 40,000 natural product structures extracted from fungi collected in Borneo's rainforests. The screen identified 23 compounds with potential anticancer activity, of which four showed selective toxicity toward triple-negative breast cancer cells in vitro. The study, funded in part by the pharmaceutical company Novartis, was reported in Science Advances.

Screening at Scale

The resurgence in natural products drug discovery owes much to technological advances that address the sector's historical bottlenecks. High-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) can now profile the metabolomic content of a tissue sample in minutes rather than days. Automated bioassay systems can screen thousands of crude extracts against disease-relevant cell lines weekly.

Perhaps most significantly, AI-driven molecular networking has transformed how researchers identify novel structures within complex biological mixtures. Tools such as GNPS (Global Natural Products Social Molecular Networking), developed at the University of California, San Diego, allow scientists to compare mass spectra from unknown compounds against databases of known molecules, flagging structurally unique candidates for further study. The platform has been used in over 1,500 published studies since its launch in 2016.

"The AI component changes the economics entirely," said Pieter Dorrestein, a professor at UC San Diego who directs the Center for Global Metabolomics Research. "You can now prioritize which extracts to pursue based on computational predictions rather than screening everything blindly. That reduces the cost per novel hit dramatically."

Bioprospecting Economics

The financial math is increasingly favorable. Developing a single drug from discovery to market approval typically costs between $1 billion and $2.6 billion, according to estimates from the Tufts Center for the Study of Drug Development. Traditional high-throughput screening of synthetic compound libraries yields approved drugs at a rate of roughly one per 100,000 compounds tested. Natural product libraries, despite their smaller size, have historically produced leads at higher rates because evolution has already optimized many molecules for biological activity.

For natural products specifically, the hit rate for bioactive compounds in crude extracts ranges from 1% to 5%, depending on the assay, compared with 0.01% to 0.1% for synthetic libraries. When researchers focus on taxonomically underexplored groups, such as deep-sea organisms or tropical microorganisms, the novelty rate increases further.

Corporate activity reflects this calculus. In the past two years, several partnerships have signaled renewed pharmaceutical interest in natural product sources:

• Ginkgo Bioworks, the Boston-based synthetic biology company, launched a dedicated natural products division in 2024 with $150 million in funding from a consortium that includes Pfizer and Bayer. The unit aims to culture previously unculturable organisms using novel bioreactor designs.

• Merck signed a five-year, $80 million collaboration with the Smithsonian Tropical Research Institute to screen marine invertebrate samples from the Indo-Pacific region for anticancer and antiviral leads.

• Japanese conglomerate Shionogi acquired a 30% stake in the natural products AI startup Evotec for approximately ¥12 billion ($85 million) in early 2025, citing the need to diversify its antibiotic pipeline beyond synthetic compounds.

Taxonomy's Bottleneck

The surge in species descriptions, while encouraging, also exposes a structural constraint. Taxonomy, the science of naming and classifying organisms, remains chronically underfunded and understaffed. The 17,044 species described in 2020 were cataloged by a shrinking global workforce of roughly 5,000 active taxonomists, many of whom operate without permanent positions. The average time from specimen collection to formal species description exceeds two years, and in some groups, such as tropical insects, a decade-long backlog is common.

This creates a disconnect. The organisms most likely to yield novel chemistry, particularly microorganisms from extreme or understudied environments, are often the slowest to be formally described and made accessible to researchers. Without a named, vouchered specimen deposited in a public collection, downstream patent applications and regulatory submissions face significant hurdles.

Efforts to address this bottleneck include the Global Soil Biodiversity Initiative, which is coordinating large-scale soil sampling across 30 countries to culture and characterize previously unknown microorganisms. The Earth BioGenome Project, an international consortium launched in 2018, aims to sequence the genomes of all known eukaryotic species by 2030, a project with an estimated budget exceeding $4.7 billion. While genome sequences are not equivalent to formal taxonomic descriptions, they provide a parallel track for identifying species with commercially relevant metabolic capabilities.

Regulatory and Ethical Dimensions

The renewed interest in bioprospecting also raises questions about access and benefit-sharing. The Nagoya Protocol, an international agreement that entered into force in 2014, governs how genetic resources and traditional knowledge are accessed and how the resulting commercial benefits are shared with source countries. Compliance adds complexity and cost to natural product research, particularly for samples collected in biodiversity-rich nations with strict sovereignty regulations.

Several pharmaceutical companies have responded by establishing local partnerships and equity-sharing models. Merck's collaboration with the Smithsonian, for example, includes provisions for returning a percentage of royalties to the Indonesian and Philippine governments for any drugs derived from samples collected in their territorial waters. Ginkgo Bioworks has invested in sequencing infrastructure in Brazil and Madagascar to build local research capacity while securing access rights to microbial collections.

The ethical calculus is not trivial. The Nagoya Protocol has been criticized by some researchers for slowing the pace of discovery, while conservation groups argue that the protocol is essential to prevent biopiracy. Finding a balance between rapid scientific progress and equitable benefit distribution remains an active area of policy debate.

What Comes Next

The convergence of accelerating species discovery, improved screening technologies, and AI-driven compound prioritization has created what many researchers describe as a golden age for natural products research. For pharmaceutical companies facing patent cliffs on blockbuster drugs and limited pipelines, the untapped chemical diversity of undocumented species represents one of the few remaining sources of genuinely novel therapeutics.

The market dynamics favor continued investment. Global spending on antibiotic resistance-related research reached $2.4 billion in 2023, according to the Wellcome Trust, but remains far below the estimated $4.1 billion annual funding gap identified by an independent review panel. Natural products, with their evolutionary track record of producing antimicrobial compounds, are well-positioned to fill parts of that gap.

For chronic diseases including cancer, autoimmune disorders, and neurodegeneration, the path from natural product discovery to approved therapy remains long and uncertain. But the data suggests that the odds are improving. Between 2015 and 2024, natural product-derived or natural product-inspired drugs accounted for 12 of the 73 new molecular entities approved by the U.S. Food and Drug Administration, a share of roughly 16%. That figure is up from approximately 9% in the preceding decade.

The organisms are out there. The tools to characterize them exist. The business case is solidifying. The remaining question is whether the institutional and financial infrastructure can scale fast enough to match the pace of biological discovery. For an industry accustomed to screening synthetic libraries of fixed size, the shift to a biosphere that continuously generates new chemistry represents a fundamental change in how drug pipelines are built. The companies that adapt most effectively stand to gain access to a resource that, by definition, never stops growing.